PHARMACONEX | CHEMI

In association with CPHI

Africa's Pharmaceutical Manufacturing Hub

Egyptian Pharmaceutical Market Research

2022-2027

Table of Contents

Part. 1

Egypt General Overview

Location

Egypt is located in the northeast of Africa and the west of Asia. It is located in the transportation hub of the three continents of Europe, Asia and Africa. It is the country with the largest population in North Africa and Arab countries and a powerful country in economy, science and technology.

Civilization

One of the world’s earliest and greatest civilizations, with a unified kingdom first surfacing around 7000 years B.C.

People Habits

- Egyptians are religious people, with more than 90% Muslims, 10% Christians.
- Famous profusions as Engineering, Medical field and agricultures.

Pharmaceutical Market

- Egypt has a strong manufacturing industry and is the largest producer and consumer of pharmaceuticals in the MENA region.
- Behind only Saudi Arabia (USD 8.5 billion) within MEA, Egypt’s pharma market has consolidated its position as the prime destination outside of the Gulf with USD 6.3 billion in value in 2021.

Egyptian Population Forecast



Source: Worldometer

- The current population of Egypt is estimated at more than 106 million, which is the most populated country in middle east.
- Egypt population is equivalent to 1.31% of the total world population.
- Egypt ranks number 14 in the list of countries (and dependencies) by population in the world.
- The population density in Egypt is 103 per Km^2 (266 people per mi^2).
- The total land area is 995,450 Km^2 (384,345 sq. miles).
- 43.0 % of the population is urban.
- The median age in Egypt is 24.6 years.

Top 10 Causes of Death

Causes of Death	World Rank
Coronary Heart Disease	15
Liver Disease	1
Stroke	110
Liver Cancer	2
Hypertension	35
Kidney Disease	46
Influenza and Pneumonia	99
Diabetes Mellitus	92
Lung Disease	100
Breast Cancer	33

Source: World Health Organization

About 70 percent of deaths in Egypt are due to chronic diseases including diabetes, heart disease, stress and cancer according to the World Health Organization official, Randa Abul-Naga. Epidemiological studies by WHO have shown that non communicable diseases, such as cancer, cardiovascular diseases (especially ischemic heart disease), diabetes and mental health diseases, are the main causes of morbidity and mortality in the region.

• Cardiovascular disease

In Egypt, cardiovascular disease accounts for about 40% of the total population, and is currently the main cause of death in Egypt. Cardiovascular disease is a chronic disease that requires a long treatment time and requires the use of a variety of different drugs. The large base of patients can promote the rapid growth of the Egyptian pharmaceutical industry.

• Cancer

Liver cancer is the most common cancer in men, followed by bladder, lung and non Hodgkin's lymphoma. Breast cancer is the most common malignancy in women, followed by liver cancer, non Hodgkin's lymphoma and brain cancer.

• Infectious disease hepatitis C

Egypt had the highest prevalence of hepatitis C virus (HCV) infection in the world as a result of the prevalence of schistosomiasis and its mass treatment by unsafe intravenous injections in the 1950s and 1960s.
Thus, it is not surprising that liver cancer, mainly hepatocellular carcinoma (HCC, which constitutes about 70.5% of all liver cancers), was the most common cancer among men (33.6%) and was the second-most common cancer among women (13.5%) after breast cancer in the National Cancer Registry Program.

• Obesity and type 2 diabetes

They're becoming increasingly prevalent worldwide, and both are associated with increased cancer incidence and mortality. Egypt has the highest obesity rate among the world's 20 most populous countries, and the prevalence of diabetes in Egyptian adults is around 15.6%.

Diseases

- One of the main drivers of the growth of the Egyptian pharmaceutical market is the aging population and chronic diseases. The emergence of respiratory diseases, heart diseases and cardiovascular diseases, especially in promoting the development of high-value prescription drugs in Egypt.

- Epidemiological studies by WHO have shown that non communicable diseases are the main cause of morbidity and mortality in Egypt. Health problems related to young people are increasingly reflecting problems in more developed countries, such as the prevalence of mental illness. There are several mainstream diseases will increase significantly.

• Chronic diseases, such as chronic respiratory diseases	(+ 58%)
• Cancer	(+ 47%)
• Ischemic heart disease	(+ 23%)
• Musculoskeletal diseases	(+ 46%)
• Mental and behavioral illness	(+ 47%)
• Cardiovascular disease	(+ 20%)

Part. 2

Egyptian Pharmaceutical Market Overview

MEA Pharma Market by Country



Source: IQVIA; PHARMA BOARDROOM

- The overall MEA pharmaceutical market reached USD 30 billion in September 2021 and, according to IQVIA's quarterly report published in January, the region's market is forecasted to reach USD 47 billion in 2022.

- Many large markets have experienced slow growth due to covid-19 lockdowns. In September of 2021, Egypt pharma market is valued at $6.3bn with a growth rate of 16.1% over last year. The rest of the top 5 includes Saudi Arabia (8.5) , South Africa (3.7), United Arab Emirates (2.8) and Algeria (2.4).

- According to QVIA, local companies account for 56% of the market in sales, while multinationals have 44%. In fact, the fast growth of region's market can be highly attributed to Egypt, beacause Eva Pharma and Sedico/Acdima are two Egyptian companies of the top 10 fastest growing companies in MEA.

APIs Market

- The production of most APIs is carried out by local pharmaceutical companies. However, Egypt's pharmaceutical market has a relatively short development time, and in the late 1980s and early 1990s, the pharmaceutical market developed rapidly. However, after entering the 21st century, the development of Egypt's pharmaceutical market began to stagnate.

- With the end of the transition period of WTO accession, the Egyptian government had to implement the TRIPS agreement and open up the pharmaceutical market, which faced a huge survival crisis for the domestic pharmaceutical companies in Egypt. It can be seen that the domestic API manufacturing capacity in Egypt is relatively weak, and the market is highly dependent on APIs produced in other regions.

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

- The in-out volume is as high as 90%. Mainly from Europe and the United States and other countries, cheap APIs are mainly supplied by China and India and other Asia country.

Export Status



Source: COMTRADE

- Egypt Exports of pharmaceutical products was US $312.63 Million during 2021, according to the United Nations COMTRADE database on international trade. Egypt Exports of pharmaceutical products - data, historical chart and statistics - was last updated on August of 2022.

- However, the government encourages exports and reduces the trade deficit. Therefore, although the export base is low, the export growth is expected to be faster than that of Egyptian drug imports. Most exports will continue to target other Middle East and North African markets, with a focus on Saudi Arabia, the United Arab Emirates, Iraq, Sudan and Jordan.

- The Minister of health of Egypt announced that many pharmaceutical production plants are still under construction, many of which will be built in industrial areas throughout the country. Exporting generic drugs is the main way for Egyptian companies to earn long-term profits, especially in maintaining low prices, which is very competitive.

Drugs

Top 100 Selling Brands in Egyptian Market Semster 1, 2022

1	CONTROLOC	26	GALVUS MET	51	AMARYL	76	GLUCOPHAGE
2	HIBIOTIC	27	ANTODINE	52	MEGAMOX	77	ENTRESTO
3	PANADOL	28	TELFAST	53	SUPRAX	78	RECOXIBRIGHT
4	AUGMENTIN	29	CEREBROLYSIN	54	BETADINE	79	FEROGLOBIN
5	ZURCAL	30	OTRIVIN	55	COMTREX	80	DAFLON
6	CLEXANE	31	GAPTIN	56	LANTUS	81	VOLTAREN
7	CONVENTIN	32	FLUMOX	57	TIRATAM	82	TAVANIC
8	ALPHINTERN	33	DIAMICRON	58	CLAVIMOX	83	GLIPTUS PLUS
9	CEFOTAX	34	OMEGA-3 PLUS	59	GONAPURE	84	PRONTOGEST
10	BRUFEN	35	XORAXON	60	ASPIRIN	85	FORXIGA
11	CONCOR	36	SYSTANE	61	CURAM	86	NEUROTON
12	EREC	37	CONGESTAL	62	CIALIS	87	CEFAXONE
13	CRESTOR	38	ZITHROMAX	63	VIAGRA	88	SAXENDA
14	XITHRONE	39	CATAFAST	64	REPARIL-GEL N	89	GYNERA
15	PLAVIX	40	ANTINAL	65	KETOLAC	90	DOLIPRANE
16	NEXIUM	41	NESTOGEN	66	ZYRTEC	91	THIOTACID
17	MILGA ADVANCE	42	DICLAC	67	BEBELAC 2	92	BIVATRACIN
18	INS MIXTARD	43	UNICTAM	68	DUPHASTON	93	FUCIDIN
19	CATAFLAM	44	CEFTRIAXONE	69	CERELAC IRON +	94	AMBEZIM-G
20	DEPOVIT B12	45	MILGA	70	CONCOR 5 PLUS	95	ACETYLCISTEIN
21	JANUMET	46	DANSET	71	OMEZ	96	FUCICORT
22	VOLTAREN	47	VIRECTA	72	EXFORGE HCT	97	DECLPPHEN
23	BEBELAC	48	KENACOMB	73	FLAGYL	98	CO-TOREG
24	BI-ALCOFAN	49	DEXAMETHASONE	74	PULMICORT	99	EPICEPHIN
25	GABIMASH	50	OPLEX-N	75	CETAL	100	BEVILOB

Source: Bepac

- Egypt's pharmaceuticals market reached about £54bn in the first half, up about 11% on last year. The top 100 selling products accounted for about $17 billion in sales, about 32% of the total sales.

- Controloc ranked toppest selling product for the first time.
- The sales of hibiotic was close to 1 billion pounds, ranking No. 2.
- Panadol ranked No. 3 in this semster.

Medical Expenditure

Health care expenditure (percentage of GDP)	4.7 %
Per capita medical expenditure (PPP)	582 international dollars
General government expenditure on health as a share of current health expenditure	27.8 %
Percentage of total government medical expenditure to total government expenditure	4.7 %
Out of pocket expenditure as a share of current health expenditure	62.7 %
Total health care expenditure	12,357 million US dollars
Social health insurance as a share of current health expenditure	7 %
Voluntary health insurance as a share of current health expenditure	6.9 %
Per capita expenditure on government health care	36 US dollars
Per capita expenditure on general health administration at purchasing power parity (NCU/ USD)	176 US dollars
Private health care expenditure (the percentage)	71.2 %

Supply and Demand

- Egypt has a strong domestic pharmaceutical industry, with about 200 pharmaceutical companies, of which less than 10 are multinational companies with local production bases.
- Egypt has the largest drug manufacturing base in the Middle East & North Africa, accounting for nearly 30% of the regional market.
- The drugs produced in Egypt can meet nearly 93% of its local demand for medicine, with 7% consisting of highly specialized pharmaceuticals that are not locally produced.
- 5% of domestic drugs are exported to the Arab region, Africa and some European countries.
- Multinational corporations account for nearly 40% of local sales through domestic manufacturing, and about 35% through licensing agreements, while the remaining percentage represents generic medicines produced by local companies.
- In Egypt, the hospital channel is carrying the load and accounts for 40% of the country's sales.

- Egypt spends a lot on medicine. 56% of health spending. Drug purchases at pharmacies account for nearly half of out-of-pocket payments. Drug prices are administered by the Ministry of Health's Central Agency for Pharmaceutical Affairs (CAPA), which sets mandatory retail prices for drugs.
- Almost all raw materials for local manufacturing need to be imported. Egypt imports about $600 million in finished medicines and $1.8 billion in active ingredients annually. Multinational companies set up factories locally, but 15-20% of medicines are imported and 80-85% are produced locally. In Egypt, about 70% of medicines are generic and domestically produced.
- Given the lack of a comprehensive health-insurance system in Egypt, the pharmaceuticalsales are based on out-of-pocket expenditures as consumers find self-medicating to be the cheapest form of treatment. Pharmaceutical sales are divided into prescription drugs and over-the-counter (OTC) drugs.
- Sales of patented drugs will outgrow that of generic drugs due to the domestic industry's heavy reliance on importing raw materials, which have surged in the past year. It should be noted, however, that the market could eventually shift favour towards generics, given their cheaper price tags, and the government's willingness to maintain cost-containment measures.

Source: Secondary Sources, Expert Interviews and WK Information

Market Segmentation

Classification of Pharmaceutical Enterprises



Private Company · Public Corporation · Joint Venture



Regional Agent · Market Share

Sales Channel

Drug Distribution

- There are two channels for the sale of drugs in Egypt: Consignment and self-supporting. The main channel is the sale of drugs through the sales network of drug distribution companies.

- At present, the largest drug distribution company in Egypt is Egydrug, a state owned Egyptian drug company, and UCP, a private joint distribution company.

- Egydrug has the largest sales network in China, with sales points all over the country. And the company pays the manufacturer in cash, while private companies generally need to sell on credit. Although the agency fee charged by the state is higher than that charged by the private sector, many companies prefer to use Egydrug as an agent.

Pharmaceutical Retail

- Pharmacies deal with foreign companies, state-owned enterprises and wholesalers. Although there are a few chain stores, most pharmacies are public. For example, El-Ezaby, which was founded in 1975 and belongs to Multipharma group, aims to become a leading pharmacy chain in the Middle East.

- Other chain stores include Misr Pharmaceuticals and Seif Pharmaceuticals, which are part of the Seif Group and mainly target high-income people.

Pharmaceutical Companies

Top 100 Selling Pharmaceutical Companies in Egyptian Market Semster 1, 2022							
1	NOVARTIS	26	NESTLE	51	CID	76	ROCHE
2	PHARCO	27	ADWIA	52	LEO	77	ROWA
3	GSK	28	CHEMIPHARM	53	BORG	78	PARKVILLE
4	AMOUN	29	SERVIER	54	JUUPHAR	79	FERRING
5	SANOFI	30	MINAPHARM	55	ZETA	80	PENTA
6	EIPICO	31	NUTRICIA	56	AVERROES	81	ORGANO
7	EVA	32	PHARAONIA	57	ACDIMA	82	HOCHSTER
8	HIKMA	33	ACINO	58	JAMJOOM	83	NASR
9	AUG	34	UTOPIA	59	HYGINT	84	LUNDBECK
10	MARCYRL	35	OCTOBER	60	COPAD	85	OTSUKA
11	APEX	36	KAHIRA	61	BOEHRINGER	86	UNI PHARMA
12	ASTRA	37	DELTA	62	MISR	87	MEDIZEN
13	HORUS	38	J & J	63	EVER	88	INFINITY
14	GNP	39	NERHADOU	64	MEMPHIS	89	DEVART
15	MASH	40	ALEXANDRIA	65	AL ESRAA	90	MULTICARE
16	ABBOTT	41	MACRO	66	EGPI	91	ADG
17	MUP	42	M.S.D	67	ADCO	92	TABUK PH
18	MERCK	43	ELI LILLY	68	LIPTIS	93	RECKITT
19	RAMEDA	44	INSPIRE	69	MUNDI	94	NUTRIBIO
20	ANDALOUS	45	ORGANON	70	EGYPHAR	95	AMGEN
21	BAYER	46	HERO	71	FPI	96	ATCO
22	NOVO	47	NILE	72	LIMITLESS	97	HEFNY
23	SEDICO	48	ORCHIDIA	73	DBK P	98	XEEDLA
24	VIATRIS	49	VITABIOTICS	74	IBSA	99	SPIMACO
25	PFIZER	50	SIGMA	75	MEPACO	100	FIDIA

Source: Bepac

- **Domestic:** leading local manufacturers include Eipico, Amoun Pharma, Pharco, MUP and Sedico. Few local pharmaceutical manufacturers in Egypt are completely state-owned, while the rest are partially or completely privatized. Public production is represented by HoldiPharma.

- **Abroad:** leading multinational companies such as Pfizer, GlaxoSmithKline and AstraZeneca are planning to expand their local businesses. The current market leaders with production facilities include Bristol Myers Squibb, GlaxoSmithKline, Novartis and Pfizer. Other leading multinational companies in the market include Servier in France and Johnson & Johnson in the United States, Lilly and Merck.

- Although many multinational companies are active in the Egyptian market, the latest report shows that few multinational companies produce directly. Many people will import or license drugs from local manufacturers. Multinational companies supply about two-thirds of the market through direct local manufacturing or licensing agreements. Due to the wide variety of products, local and foreign companies tend to specialize, which makes the Egyptian drug market highly fragmented.

Local Manufacturers

- **Pharco Pharmaceuticals** is the founder of the corporation and is the second private Egyptian shareholding pharmaceutical company established in 1984. It started production in 1987 formulating, producing and marketing about 450 brands, generics, branded generics and licensed products to date.
- Pharco Pharmaceuticals has scientific offices; KSA, Yemen, UAE, Bahrain, Lebanon, Libya and Romania and exports to 50+ countries. Throughout the years Pharco Pharmaceuticals has created several brands which have become market leaders in both local and international markets; Gratisovir 400mg, Rani effervescent, Fawar Fruit, Ciprofar 500 MG tablets, Spasmo Digestin, Delcophen amp, Royal jelly, Uricol effervescent, Urinex caps, Bilichol caps, Mirazid and Baby Drink. Currently a major cardiovascular line is up to date.

- **APC (Amoun)** is the largest domestic pharmaceutical manufacturer in Egypt and the domestic company with the highest income, ranking third overall. The company currently has five branches in Egypt, producing human and veterinary medicine products and nutritional supplements. APC is the first private drug company established in the country to import and distribute drugs.
- APC's product portfolio includes anesthetics, analgesics, gastrointestinal drugs, endocrine drugs, topical preparations, cardiovascular drugs, vitamins and minerals.
- APC also aims to increase its exports, aiming to become "Egypt's leading drug exporter".

- **EIPICO** is currently one of the leading Egyptian pharmaceutical companies, in terms of production and sales, in the local market. It is the leading company in pharmaceutical exports, capturing a 21% share of the total Egyptian pharmaceutical export market.

- EIPICO produces antibiotics, antifungal drugs, dysentery drugs, antihistamines, antimalarial drugs, blood substitutes, antihypertensive drugs and cardiovascular drugs, central nervous system (CNS) drugs, dermatological treatment, endocrine and ophthalmic treatment, and steroid antiinflammatory drugs.

EVA PHARMA

- **EVA Pharma** has been established since 1997. It is one of the leading pharmaceutical Egyptians companies in MENA region that is built on the heritage of Les Laboratories Delta, the second oldest pharmaceutical Egyptian company. Recently, EVA Pharma becomes one of the leading branded generic pharmaceutical manufacturers in the MENA region with a CAGR (Compound Annual Growth Rate) of 22.5% over the last three years enabling EVA Pharma to be one of the fastest-growing pharmaceutical companies in the region.

- **MUP (Medical Union pharmaceuticals)**, one of the largest domestic pharmaceutical manufacturers in Egypt. The pharmaceutical alliance pharmaceutical company also has a representative office in Kazakhstan, indicating its ambition for the Commonwealth of Independent States.
- Medical Union pharmaceuticals manufactures and distributes drugs, cosmetics and special foods in Egypt and abroad.
- Medical Union pharmaceuticals is mainly concentrated in the local market of Egypt, and most of its sales are carried out in the local market, while less through public sector bidding.

- **SEDICO** is one of the most outstanding local companies, focusing on generic drugs, but it also has three patented products in its product portfolio, and is one of the leading insulin manufacturers.
- SEDICO's product portfolio includes analgesics, antihistamines and nasal congestion drugs, antidepressants and cardiovascular drugs.

Manapharma, is considered one of the top and oldest companies in Egypt working as agent and exclusively representing many international API companies from the US, Europe and Asia over the past 35 years. In this regards, Manapharma supports and supply the majority of local pharmaceutical finished products manufacturers in Egypt with APIs and Excipients.

Chemical Maker is a leading company working in the Egyptian market since 2005. The company is a marketing company in the field of pharmaceutical market. They are supporting our customer with providing the Active pharma ingredients (API), and chemical Reagents used in their labs for the analysis. Their suppliers are all GMP certified and mostly have DMF, USFDA, and CEP.

Part. 3

Regulatory Bodies in Egyptian Pharmaceutical Market

Regulatory Bodies



Source: The Pharma Letter

- The regulatory framework leading the pharmaceutical industry in Egypt has been entirely restructured according to the Egyptian Law No. 151 of 2019, which declared the establishment of the Egyptian Drug Authority (EDA) as its own entity and the Egyptian Authority for Unified Procurement, Medical Supply and Technology Management as a separate economic unit , aiming for conceptualizing, developing, and strengthening the healthcare system and pharmaceutical industry in Egypt.

- With an ambitious target of boosting the pharmaceutical industry in Egypt, the new Egyptian government has issued a package of laws to improve the pharmaceutical sector in Egypt. Nevertheless, additional regulations are still necessary and important to implement.

EDA

- The Egyptian Drug Authority (EDA) is established as a public service authority affiliated to the Prime Minister to be responsible for all drug related matter.
- EDA will be the regulatory authority responsible solely for the registration, licensing, inspection and supervision of all pharmaceutical and cosmetic products, medical equipment and raw materials used in their manufacturing.

EDA has replaced following entities:

- National Organization for Drug Control and Research (NODCAR).
- National Organization for Research and Control of Biological (NORCB).
- Central Administration of Pharmaceutical Affairs (CAPA) in relation to the registration and licensing or pharmaceutical products.

The main responsibilities of EDA will be, among others, the following:

- Issuance of the necessary licenses for all pharmaceutical entities.
- Issuance of the operation licenses for factories of pharmaceutical products and medical equipment.
- Licensing private laboratories that are working in the pharmaceutical field.
- Examination of all pharmaceutical, biological products like medicines, cosmetics, insecticides, vaccines, serums, pharmaceutical devices, tools, medical lenses, diagnostic indicators in order to insure their quality, safety, effectiveness and compliance with the approved.
- Setting the rules and procedures for importation, exportation and pricing of all pharmaceutical products and medical equipment.
- Customs release of all imported pharmaceutical products and medical equipment.
- Licensing locally manufactured products and equipment.
- Issuance of the Egyptian Pharmacopeia.
- Inspection of all pharmaceutical entities and their officers and taking necessary legal actions against violations.

Part. 4

Egyptian Pharmaceutical Market Dynamics

Opportunities

1 Rapid population growth and urbanization. From 1986 to 2022, the population of Egypt more than doubled, from 48 million to 106 million, ranking 14th in the world. The expanding market demand created opportunities for pharmaceutical companies.

2 The population is aging gradually, and the burden of long-term chronic diseases is increasing, which leads to the increasing demand for therapeutic drugs in the market. Aging weakens the immune system and increases a patient's susceptibility to infectious diseases. In addition, impaired physical function increases the chance of developing other diseases, such as cardiovascular disease and diabetes. Egypt is undergoing a demographic transition, with the number of people over 60 expected to more than double between 2020 and 2050, from 8.4 million (8% of the population) to 22 million (14%).

3 Egypt is currently a member of the common market for Eastern and southern Africa, the European Free Trade Association, GAFTA, Agadir, the EU partnership and QIZ. In addition, Egypt also took the lead in signing the trilateral free trade agreement, which integrates the three major African free trade agreements - COMESA, SADC and EAC - and uses its price competitive advantage over the international market to continuously develop the African market.

4 According to Egypt's 2030 vision, the Egyptian government is committed to promoting the construction of a comprehensive medical insurance system. In 2019, the National Medical Insurance Bureau (UHA) was newly established, and the medical insurance funds will mainly come from the payment of the insured. Individuals can pay 5% of the total salary to become the insured, and also through IMF and other international organizations.

The new universal medical insurance system is planned to be implemented in six stages. The first phase of 2020 starts from the pilot projects in six provinces, and it is planned to complete full coverage by 2032. Egypt's current president Sisi is expected to be in power until 2030 after amending the constitution, providing political guarantee for the promotion of universal health insurance, and the future investment in health care is expected to continue to increase.

Risks

- Insufficient product innovation and lack of international qualification certification.
- Strong public centralized purchase and price reduction.
- There is no comprehensive medical insurance system, and drug sales are based on out of pocket expenses.
- Bulk drugs are highly dependent on import.
- The production cost is high and the development potential is insufficient.
- Industrial policies favor domestic demand, resulting in weak exports.
- Surmount the regulatory obstacles of the economic environment - the delay in the approval of government licenses, the lax implementation of intellectual property rights, and poor pricing plans.
- Egypt’s currency devaluation and reform measures, such as cutting fuel and energy subsidies and implementing the new value-added tax law, have led to huge inflationary pressures.



Part. 5

Egyptian APIs Market Forecast

Revenue and Growth Rate



- The Egypt APIs revenue will be steadily increase in the future, and it is estimated to reach 3252.76 million USD in 2027. The growth rate has reached a peak in 2022, and it will gradually slow down in the next few years.

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Revenue and Market Share by Type

Egypt APIs Revenue Forecast by Type (2022-2027) (M USD)						
By Type	2022	2023	2024	2025	2026	2027
Synthetic	2022.06	2113.07	2218.58	2326.88	2420.59	2420.59
Biological	410.71	432.53	454.46	476.66	494.84	512.31
Plant Extracts	169.96	178.13	185.21	196.18	200.68	206.22
Total	2602.73	2723.73	2858.25	2999.72	3116.11	3252.76

Egypt APIs Market Share Forecast by Type (2022-2027) (M USD)						
By Type	2022	2023	2024	2025	2026	2027
Synthetic	77.69%	77.58%	77.62%	77.57%	77.68%	77.91%
Biological	15.78%	15.88%	15.90%	15.89%	15.88%	15.75%
Plant Extracts	6.53%	6.54%	6.48%	6.54%	6.44%	6.34%
Total	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Revenue and Market Share by Application

Egypt APIs Revenue Forecast by Application (2022-2027) (M USD)

By Application	2022	2023	2024	2025	2026	2027
Pharmaceutical & Biotechnological Industry	1537.43	1607.54	1685.52	1780.63	1850.97	1944.83
CROs	350.85	363.35	387.29	403.16	420.05	433.92
CMOs	206.14	216.81	230.37	240.88	248.98	258.59
Others	508.31	536.03	555.07	575.05	596.11	615.42
Total	2602.73	2723.73	2858.25	2999.72	3116.11	3252.76

Egypt APIs Market Share Forecast by Application (2022-2027) (M USD)

By Application	2022	2023	2024	2025	2026	2027
Pharmaceutical & Biotechnological Industry	59.07%	59.02%	58.97%	59.36%	59.40%	59.79%
CROs	13.48%	13.34%	13.55%	13.44%	13.48%	13.34%
CMOs	7.92%	7.96%	8.06%	8.03%	7.99%	7.95%
Others	19.53%	19.68%	19.42%	19.17%	19.13%	18.92%
Total	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Source: Secondary Sources, Expert Interviews and WK Information Research, 2022

Get in touch with us

PHARMACONEX
In association with CPHI
Africa's Pharmaceutical Manufacturing Hub

Find out more about exhibiting and
sponsorship opportunities at Pharmaconex

Local & International Sales:

Samar Awad | Exhibition Manager
+2010 2444 5031
samar.awad@informa.com

India sales:

Ms. Shruti Save
Mobile: +91 9773 4066 28
shruti.save@informa.com

Mr. Sameer N. Matkar
Mobile : +91 986 7293 605
Sameer.Matkar@informa.com

PharmaconexEgypt
Pharmaconex-egypt

China sales:

Jennie Zhan| Account Manager
+86 138 284 18180
Jennie.Zhan@informa.com

Book a Stand at Pharmaconex 2023

Scan Me!

ECHEMI

Contact Us

Public Relations:
info@echemi.com

International Marketing:
marketing@echemi.com

Membership Services:
service@echemi.com